Invivo therapeutics provides enrollment update for inspire 2.0 study for the treatment of acute spinal cord injury

Invivo therapeutics holdings corp. announced that a total of five patients have been enrolled into the inspire 2.0 study (invivo study of probable benefit of the neuro-spinal scaffold™ for safety and neurologic recovery in subjects with complete thoracic ais a spinal cord injury), bringing the study to 25% completion of targeted enrollment. the first patient was enrolled into the inspire 2.0 study in may of 2019, and 14 sites are currently open for enrollment into the study.
NVIV Ratings Summary
NVIV Quant Ranking